Who are Apilimod Dimesylate Capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fingolimob (FTY), Group S+T, FTY720, Placebo to ozanimod, NU100, zilucoplan (RA101495).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apilimod-dimesylate-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Apilimod Dimesylate Capsule — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apilimod Dimesylate Capsule (Apilimod Dimesylate Capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine 1-phosphate receptor modulator. Area: Immunology.

phase 2 Sphingosine 1-phosphate receptor modulator S1P1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Apilimod Dimesylate Capsule (Apilimod Dimesylate Capsule) — OrphAI Therapeutics. Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Apilimod Dimesylate Capsule TARGET	Apilimod Dimesylate Capsule	OrphAI Therapeutics	phase 2	Sphingosine 1-phosphate receptor modulator	S1P1
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)
Group S+T	Group S+T	Huazhong University of Science and Technology	marketed	S1P receptor modulator	S1P1
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Placebo to ozanimod	Placebo to ozanimod	Celgene	phase 3	Sphingosine-1-phosphate (S1P) receptor modulator	S1P1 and S1P5 receptors
NU100	NU100	Nuron Biotech Inc.	phase 3	S1P1 receptor modulator	S1P1
zilucoplan (RA101495)	zilucoplan (RA101495)	UCB Biopharma SRL	phase 3	S1P receptor modulator	S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine 1-phosphate receptor modulator class)

OrphAI Therapeutics · 1 drug in this class
Pfizer · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apilimod Dimesylate Capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/apilimod-dimesylate-capsule. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab